Published in Gastroenterology on June 01, 2006
Direct infection and replication of naturally occurring hepatitis C virus genotypes 1, 2, 3 and 4 in normal human hepatocyte cultures. PLoS One (2008) 1.09
Hepcidin and the iron enigma in HCV infection. Virulence (2014) 0.88
Pathogenic Role of Iron Deposition in Reticuloendothelial Cells during the Development of Chronic Hepatitis C. Int J Hepatol (2013) 0.84
Iron deposition and fat accumulation in dimethylnitrosamine-induced liver fibrosis in rat. World J Gastroenterol (2007) 0.82
Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33
Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med (2011) 6.31
Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology (2004) 6.14
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Liver cirrhosis. Lancet (2008) 6.11
Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med (2007) 5.13
Exceeding the limits of liver histology markers. J Hepatol (2008) 5.06
Herbal hepatotoxicity. J Hepatol (2005) 3.98
IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology (2010) 3.57
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30
Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology (2006) 2.96
Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. J Clin Invest (2008) 2.89
Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis. Hepatology (2008) 2.76
Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol (2005) 2.64
Wheat amylase trypsin inhibitors drive intestinal inflammation via activation of toll-like receptor 4. J Exp Med (2012) 2.58
Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS (2005) 2.34
Diagnosis and quantitation of fibrosis. Gastroenterology (2008) 2.20
Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition. J Hepatol (2011) 2.20
Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies. Hepatology (2009) 2.16
Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology (2006) 2.11
Update on serologic testing in celiac disease. Am J Gastroenterol (2010) 2.07
Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology (2010) 2.06
Liver stiffness is directly influenced by central venous pressure. J Hepatol (2009) 2.00
The incidence and clinical spectrum of refractory celiac disease in a north american referral center. Am J Gastroenterol (2011) 1.96
Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS (2007) 1.92
Tissue transglutaminase does not affect fibrotic matrix stability or regression of liver fibrosis in mice. Gastroenterology (2011) 1.85
Etiologies and predictors of diagnosis in nonresponsive celiac disease. Clin Gastroenterol Hepatol (2007) 1.82
The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol (2009) 1.77
Non-Celiac Gluten sensitivity: the new frontier of gluten related disorders. Nutrients (2013) 1.74
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology (2010) 1.74
Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology (2007) 1.73
Failure of fibrotic liver regeneration in mice is linked to a severe fibrogenic response driven by hepatic progenitor cell activation. Am J Pathol (2013) 1.73
The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol (2007) 1.73
Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. Gastroenterology (2008) 1.69
Helicobacter pylori moves through mucus by reducing mucin viscoelasticity. Proc Natl Acad Sci U S A (2009) 1.64
Serum hyaluronate correlates with histological progression in alcoholic liver disease. Eur J Gastroenterol Hepatol (2003) 1.64
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Gastroenterology (2013) 1.63
Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol (2011) 1.62
Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J Hepatol (2005) 1.62
Novel engineered targeted interferon-gamma blocks hepatic fibrogenesis in mice. Hepatology (2011) 1.61
Sublethal heat treatment promotes epithelial-mesenchymal transition and enhances the malignant potential of hepatocellular carcinoma. Hepatology (2013) 1.59
Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. J Hepatol (2011) 1.59
Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology (2011) 1.53
[Prevalence of circulating autoantibodies in healthy individuals]. Med Klin (Munich) (2002) 1.52
Mortality excess in individuals with elevated IgA anti-transglutaminase antibodies: the KORA/MONICA Augsburg cohort study 1989-1998. Eur J Epidemiol (2006) 1.51
Pathomechanisms in celiac disease. Int Arch Allergy Immunol (2003) 1.51
Serum connective tissue markers as predictors of advanced fibrosis in patients with chronic hepatitis B and D. Turk J Gastroenterol (2011) 1.48
Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res (2008) 1.48
Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. J Hepatol (2008) 1.47
Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1. J Hepatol (2011) 1.47
Endoscopic ultrasound-guided endoscopic necrosectomy of the pancreas: is irrigation necessary? Surg Endosc (2011) 1.46
Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol (2003) 1.45
EUS-guided alcohol ablation of an insulinoma. Gastrointest Endosc (2006) 1.45
Celiac crisis is a rare but serious complication of celiac disease in adults. Clin Gastroenterol Hepatol (2010) 1.40
Halofuginone induces matrix metalloproteinases in rat hepatic stellate cells via activation of p38 and NFkappaB. J Biol Chem (2006) 1.40
Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology (2007) 1.40
Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis. Hepatology (2009) 1.39
Acupuncture and moxibustion in the treatment of ulcerative colitis: a randomized controlled study. Scand J Gastroenterol (2006) 1.38
Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology (2007) 1.38
Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. J Clin Pharmacol (2009) 1.37
Kinetics of the histological, serological and symptomatic responses to gluten challenge in adults with coeliac disease. Gut (2012) 1.37
Trichostatin A, a histone deacetylase inhibitor, suppresses collagen synthesis and prevents TGF-beta(1)-induced fibrogenesis in skin fibroblasts. Exp Cell Res (2002) 1.36
EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochem Pharmacol (2005) 1.35
A solid-state NMR study of phospholipid-cholesterol interactions: sphingomyelin-cholesterol binary systems. Biophys J (2002) 1.35
Comparison of transient elastography, serum markers and clinical signs for the diagnosis of compensated cirrhosis. J Gastroenterol Hepatol (2010) 1.33
Activation of tumor-specific T lymphocytes by radio-frequency ablation of the VX2 hepatoma in rabbits. Cancer Res (2003) 1.33
Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. World J Gastroenterol (2008) 1.31
Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis. Hepatology (2006) 1.30
Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology (2004) 1.30
World Gastroenterology Organisation global guidelines on celiac disease. J Clin Gastroenterol (2013) 1.29
Rheology of gastric mucin exhibits a pH-dependent sol-gel transition. Biomacromolecules (2007) 1.29
Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. J Hepatol (2004) 1.28
Diagnosing fibrosis in hepatitis C: is the pendulum swinging from biopsy to blood tests? Hepatology (2003) 1.27
Acupuncture and moxibustion in the treatment of active Crohn's disease: a randomized controlled study. Digestion (2004) 1.26
Hyperferritinaemia-cataract syndrome: worldwide mutations and phenotype of an increasingly diagnosed genetic disorder. Hum Genomics (2010) 1.25
The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J Hepatol (2002) 1.25
A simple validated gluten-free diet adherence survey for adults with celiac disease. Clin Gastroenterol Hepatol (2009) 1.24
HIV and HCV cooperatively promote hepatic fibrogenesis via induction of reactive oxygen species and NFkappaB. J Biol Chem (2010) 1.24
Hepatitis C virus-replicating hepatocytes induce fibrogenic activation of hepatic stellate cells. Gastroenterology (2005) 1.24
Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysis. Hepatology (2007) 1.23
Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells. Biochem Pharmacol (2006) 1.21
The etiology of liver damage imparts cytokines transforming growth factor beta1 or interleukin-13 as driving forces in fibrogenesis. Hepatology (2009) 1.21
Human T cell microparticles circulate in blood of hepatitis patients and induce fibrolytic activation of hepatic stellate cells. Hepatology (2010) 1.20
Pathomechanisms in celiac disease. Best Pract Res Clin Gastroenterol (2005) 1.18
Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment. J Hepatol (2012) 1.18
Macrophage-mediated phagocytosis of apoptotic cholangiocytes contributes to reversal of experimental biliary fibrosis. Am J Physiol Gastrointest Liver Physiol (2010) 1.17
Patients with a non-dysferlin Miyoshi myopathy have a novel membrane repair defect. Traffic (2006) 1.17
Keratin variants associate with progression of fibrosis during chronic hepatitis C infection. Hepatology (2006) 1.14
Effect of HMG-CoA reductase inhibitors on proliferation and protein synthesis by rat hepatic stellate cells. J Hepatol (2003) 1.14
Biopsy or biomarkers: is there a gold standard for diagnosis of liver fibrosis? Clin Chem (2004) 1.13
Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics. J Hepatol (2005) 1.13
Ultrasound-based hepatic elastography: origins, limitations, and applications. J Clin Gastroenterol (2010) 1.12
Differential modulation of rat hepatic stellate phenotype by natural and synthetic retinoids. Hepatology (2004) 1.12
Factors that influence adherence to a gluten-free diet in adults with celiac disease. Dig Dis Sci (2008) 1.12
Hepatocyte transplantation activates hepatic stellate cells with beneficial modulation of cell engraftment in the rat. Hepatology (2005) 1.12
Atomic force microscopy reveals aggregation of gastric mucin at low pH. Biomacromolecules (2005) 1.11
Mass-encoded synthetic biomarkers for multiplexed urinary monitoring of disease. Nat Biotechnol (2012) 1.10
The receptor for advanced glycation end products is highly expressed in the skin and upregulated by advanced glycation end products and tumor necrosis factor-alpha. J Invest Dermatol (2006) 1.09
Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. J Hepatol (2011) 1.09